Regeneron Pharmaceuticals, Inc.

NASDAQ:REGN   3:59:57 PM EDT
597.41
+2.99 (+0.50%)
Products

Regeneron Says FDA Accepts Dupixent® (Dupilumab) For Priority Review In Adults With Prurigo Nodularis

Published: 05/31/2022 05:08 GMT
Regeneron Pharmaceuticals, Inc. (REGN) - FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults With Prurigo Nodularis.
FDA Accepts Dupixent® (dupilumab) for Priority Review in Adults With Prurigo Nodularis.
Regeneron Pharmaceuticals Inc- Target Action Date for FDA Decision is September 30, 2022.
Regeneron - Sbla is Supported by Data From Two Pivotal Phase 3 Trials Evaluating Efficacy, Safety of Dupixent in Patients 18 Years and Older.